Long-acting inhaled beta2-agonists in asthma therapy

Chest
R H MooreB F Dickey

Abstract

To review the pharmacology of the long-acting inhaled beta2-agonists, salmeterol and formoterol, summarize results of their clinical trials, evaluate their safety records, and discuss their roles in the treatment of asthma. Preclinical and clinical studies involving salmeterol or formoterol were identified by a MEDLINE search, weekly computerized literature updates, and manual searches. Studies of satisfactory quality were chosen for review. Salmeterol and formoterol are potent and selective beta2-adrenoceptor agonists with durations of action >12 h. Their major differences are that formoterol has a rapid onset of action and is a partial agonist of high intrinsic efficacy, whereas salmeterol has a delayed onset and is a partial agonist of low intrinsic efficacy. Twice daily use of either drug results in improved lung function, reduced symptoms, and a better quality of life. These agents protect against exercise-induced asthma for 12 h and eliminate nighttime awakening in most patients. Limited tolerance develops, especially to their bronchoprotective effects, but their improvement of lung function is sustained. Regular use of salmeterol or formoterol provides subjective and objective amelioration of asthma in patients experienc...Continue Reading

References

Dec 1, 1979·The Journal of Allergy and Clinical Immunology·S AndersonD A Lindsay
May 1, 1978·The Journal of Pediatrics·M KattanH Levison
Mar 1, 1992·British Journal of Clinical Pharmacology·J G Maconochie, J K Forster
Jun 1, 1992·The Journal of Allergy and Clinical Immunology·J M HenriksenS Pedersen
Aug 1, 1992·Archives of Disease in Childhood·C P Green, J F Price
Oct 22, 1992·The New England Journal of Medicine·B J O'ConnorP J Barnes
Nov 12, 1992·The New England Journal of Medicine·D S PearlmanS W Yancey
Nov 1, 1992·The Journal of Allergy and Clinical Immunology·F E SimonsA B Becker
Nov 1, 1992·The American Review of Respiratory Disease·B J WongF E Hargreave
Jan 1, 1992·European Journal of Clinical Pharmacology·D NowakH Magnussen
Apr 1, 1992·The Journal of Allergy and Clinical Immunology·E Y DeromM E Van der Straeten
May 1, 1991·The American Review of Respiratory Disease·E H RamsdaleP M O'Byrne
Sep 1, 1991·The American Review of Respiratory Disease·H C GongoraA E Tattersfield
Oct 1, 1991·The American Review of Respiratory Disease·I Erjefält, C G Persson
Nov 1, 1991·British Journal of Pharmacology·P R ButchersM Johnson
Jan 1, 1990·Lung·P R HekkingP Zweers
Oct 1, 1990·Chest·F P MaesenP G Zweers
Dec 1, 1990·Lancet·O P TwentymanS T Holgate
Nov 1, 1990·British Journal of Hospital Medicine·P W Ind
Dec 7, 1985·British Medical Journal·G B RhindD C Flenley

❮ Previous
Next ❯

Citations

Dec 22, 2004·Annals of Allergy, Asthma & Immunology : Official Publication of the American College of Allergy, Asthma, & Immunology·Gregory B DietteAlbert W Wu
Jun 28, 2001·Annals of Allergy, Asthma & Immunology : Official Publication of the American College of Allergy, Asthma, & Immunology·S L Spector, UNKNOWN Antileukotriene Working Group
Dec 29, 1998·The New England Journal of Medicine·I Aziz, B J Lipworth
Sep 11, 2001·American Journal of Respiratory and Critical Care Medicine·R DahlUNKNOWN Formoterol in Chronic Obstructive Pulmonary Disease I Study Group
May 23, 2002·American Journal of Respiratory and Critical Care Medicine·Nicola A HananiaBurton F Dickey
Sep 19, 2006·American Journal of Respiratory Cell and Molecular Biology·Robert H MooreRichard B Clark
Feb 24, 2001·The Journal of Asthma : Official Journal of the Association for the Care of Asthma·M J Massanari
Jul 5, 2005·Expert Opinion on Investigational Drugs·D A Handley, J Morley
Nov 26, 2015·International Journal of Cancer. Journal International Du Cancer·Míriam ToledoJosep M Argilés
Apr 12, 2002·Chest·Andrea RossiUNKNOWN Formoterol in Chronic Obstructive Pulmonary Disease (FICOPD) II Study Group
Jul 24, 2010·Cytometry. Part a : the Journal of the International Society for Analytical Cytology·John HolleranJonathan W Jarvik
Jul 9, 2004·The Journal of Allergy and Clinical Immunology·Elena GolevaDonald Y m Leung
Sep 24, 2004·Journal of Pharmacological and Toxicological Methods·Michael MarkertBrian Guth
Apr 12, 2016·Journal of Cachexia, Sarcopenia and Muscle·Míriam ToledoSílvia Busquets
Feb 18, 2005·Respiratory Medicine·Malcolm R Sears, Jan Lötvall
Jun 10, 2003·Emergency Medicine Clinics of North America·Brian K Adams, Rita K Cydulka
Oct 1, 2007·Therapeutic Advances in Respiratory Disease·Mario Cazzola, Maria Gabriella Matera
Apr 28, 2017·Chemistry : a European Journal·Charlotte MartinSteven Ballet
May 1, 2002·Current Protocols in Pharmacology·Brendan J Canning
Apr 16, 2010·The Cochrane Database of Systematic Reviews·Francine M DucharmeToby J Lasserson
Dec 3, 2009·Alternatives to Laboratory Animals : ATLA·Robert A Coleman
Apr 2, 2005·The Journal of Asthma : Official Journal of the Association for the Care of Asthma·Gene L ColiceL Clark Paramore
Jul 20, 1999·Journal of Chromatography. B, Biomedical Sciences and Applications·M ZhangJ P Shaw
Nov 11, 2021·Expert Opinion on Pharmacotherapy·W Tatiana Garzon-SiatoyaAlexei Gonzalez-Estrada

❮ Previous
Next ❯

Related Concepts

Related Feeds

Adrenergic Receptors: Trafficking

Adrenergic receptor trafficking is an active physiological process where adrenergic receptors are relocated from one region of the cell to another or from one type of cell to another. Discover the latest research on adrenergic receptor trafficking here.

Asthma

This feed focuses in Asthma in which your airways narrow and swell. This can make breathing difficult and trigger coughing, wheezing and shortness of breath.

Allergy and Asthma

Allergy and asthma are inflammatory disorders that are triggered by the activation of an allergen-specific regulatory t cell. These t cells become activated when allergens are recognized by allergen-presenting cells. Here is the latest research on allergy and asthma.